SAN DIEGO, May 30, 2019 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical
company focused on developing best-in-class, oral therapies
for the treatment of chronic inflammatory and autoimmune diseases,
today announced management's participation in a number of
scientific and investor conferences in June:
- June 3-6: 2nd
Conference on Molecular Mechanisms of Inflammation:
Hella Kohlhof, Ph.D., Chief
Scientific Officer of Immunic, will present newly available
preclinical data on IMU-935, an orally available, inverse agonist
of RORγt for the treatment of various inflammatory and autoimmune
diseases. The poster presentation will take place at the
2nd Conference on Molecular Mechanisms of Inflammation
in Trondheim, Norway on
Tuesday, June 4, beginning at
6:00 pm CEST.
- June 3-6: 2019 BIO
International Convention: Immunic's business development team
will attend the 2019 BIO International Convention being held in
Philadelphia June 3-6.
- June 24-26: GI
Inflammatory Diseases Summit (GIIDS): Dr. Kohlhof will
provide a presentation on IMU-838, an orally available,
next-generation selective immune modulator in development for the
treatment of inflammatory bowel disease (IBD) and multiple
sclerosis (MS), including newly available preclinical and clinical
data, at the GIIDS in Boston on
Monday, June 24 at 3:30 pm ET.
- June 25: BMO 2019
Prescriptions for Success Healthcare Conference: Daniel Vitt, Ph.D., Chief Executive Officer and
President of Immunic, will present a company overview at the BMO
2019 Prescriptions for Success Healthcare Conference in
New York on Tuesday, June 25 at 4:00
pm ET. A live audio webcast of the presentation will be
available on the "Events and Presentations" section of Immunic's
website at ir.immunic-therapeutics.com. An archived replay will be
available on the company's website for a period of 90 days after
the conference.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX)
is a clinical-stage biopharmaceutical company developing a
pipeline of selective oral immunology therapies aimed at treating
chronic inflammatory and autoimmune diseases, including ulcerative
colitis, Crohn's disease, relapsing-remitting multiple sclerosis,
and psoriasis. The company is developing three small molecule
products: IMU-838 is a selective immune modulator that inhibits the
intracellular metabolism of activated immune cells by blocking the
enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856
targets the restoration of the intestinal barrier function.
Immunic's lead development program, IMU-838, is in phase 2 clinical
development for ulcerative colitis and relapsing-remitting multiple
sclerosis, with an additional phase 2 trial in Crohn's disease
planned for 2019. An investigator-sponsored proof-of-concept
clinical trial for IMU-838 in primary sclerosing cholangitis is
planned to start at the Mayo Clinic. For further information,
please visit: www.immunic-therapeutics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
management's participation in scientific and investor conferences.
Immunic may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in the
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, risks
and uncertainties associated with the ability to project future
cash utilization and reserves needed for contingent future
liabilities and business operations, the availability of sufficient
resources to meet business objectives and operational requirements,
the fact that the results of earlier studies and trials may not be
predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual property,
risks related to the drug development and the regulatory approval
process and the impact of competitive products and technological
changes. Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that
exist after the date on which they were made.
Contact Information
Immunic, Inc.
Jessica
Breu
Manager IR and Communications
+49 89 250 0794 69
jessica.breu@immunic.de
Or
Rx Communications Group
Melody Carey
+1-917-322-2571
immunic@rxir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-june-300858960.html
SOURCE Immunic, Inc.